Delivery of noggin-siRNA up-regulates osteogenic differentiation of mesenchymal stem cells
SUN Xingkun1,LI Hong2,and WANG Lijun1
1.Department of Maxillofacial Surgery,General Hospital of Chinese People’s Armed Police Force,Beijing 100039,China; 2. Department of Advanced Interdisciplinary Studies, Institute of Basic Medical Sciences, Beijing 100039, China
Abstract：Objective To investigate whether delivery of noggin-siRNA has a strong osteogenic effect on MSCs.Methods Noggin-siRNA was transferred into MSC with a transfection reagent. The cell phenotype and proliferation of MSCs were tested by flow cytometry and MTT assay, respectively. The osteogenesis of MSCs was tested by ALP staining, QRT-PCR and Western Blotting, respectively.Results Compared with the control group, the cell phenotype and growth curve of MSC did not change significantly while the proportion of ALP positive cells and the expression of osteogenesis related genes and proteins were significantly increased.Conclusions The delivery of Noggin-siRNA can enhance osteogenesis of MSCs safely, reliably and efficiently.
Fan J,Park H,Tan S,et al. Enhanced osteogenesis of adipose derived stem cells with Noggin suppression and delivery of BMP-2[J]. PLoS One,2013,8(8):e72474.
[2]
Nkenke E,Weisbach V,Winckler E,et al. Morbidity of harvesting of bone grafts from the iliac crest for preprosthetic augmentation procedures: a prospective study[J]. Int J Oral Maxillofac Surg,2004,33(2):157-163.
[3]
Schultheiss J,Seebach C,Henrich D,et al. Mesenchymal stem cell (MSC) and endothelial progenitor cell (EPC) growth and adhesion in six different bone graft substitutes[J]. Eur J Trauma Emerg Surg,2011,37(6):635-644.
[4]
Hao W,Dong J,Jiang M,et al. Enhanced bone formation in large segmental radial defects by combining adipose-derived stem cells expressing bone morphogenetic protein 2 with nHA/RHLC/PLA scaffold[J]. Int Orthop,2010,34(8):1341-1349.
[5]
Cui Z K,Fan J,Kim S,et al. Deliveryof siRNA via cationic Sterosomes to enhance osteogenic differentiation of mesenchymal stem cells[J]. J Control Release,2015,217:42-52.
[6]
Lu C H,Chang Y H,Lin S Y,et al. Recent progresses in gene delivery-based bone tissue engineering[J]. Biotechnol Adv,2013,31(8):1695-1706.
[7]
Cheema S K,Chen E,Shea L D,et al. Regulation and guidance of cell behavior for tissue regeneration via the siRNA mechanism[J]. Wound Repair Regen,2007,15(3):286-295.
[8]
Choi B,Cui Z K,Kim S,et al. Glutamine-chitosan modified calcium phosphate nanoparticles for efficient siRNA delivery and osteogenic differentiation[J]. HHS Public Access,2015,3(31):6448-6455.
[9]
Kilgore M L,Morrisey M A,Becker D J,et al. Health care expenditures associated with skeletal fractures among medicare beneficiaries,1999-2005[J]. J Bone Miner Res,2009,24(12):2050-2055.
[10]
Evans C H,Ghivizzani S C,Robbins P D. Progress and prospects: genetic treatments for disorders of bones and joints[J]. Gene Ther,2009,16(8):944-952.
[11]
Evans C H,Ghivizzani S C,Robbins P D. Orthopedic gene therapy in 2008[J]. Mol Ther,2009,17(2):231-244.
[12]
Zhang Y,Satterlee A,Huang L. In vivo gene delivery by nonviral vectors:overcoming hurdles?[J]. Mol Ther,2012,20(7):1298-1304.
[13]
Vannucci L,Lai M,Chiuppesi F,et al. Viral vectors: a look back and ahead on gene transfer technology[J]. New Microbiol,2013,36(1):1-22.
Yan J,Zhang C,Zhao Y,et al. Non-viral oligonucleotide antimiR-138 delivery to mesenchymal stem cell sheets and the effect on osteogenesis[J]. Biomaterials,2014,35(27):7734-7749.
[16]
Yau W W,Rujitanaroj P O,Lam L,et al. Directing stem cell fate by controlled RNA interference[J]. Biomaterials,2012,33(9):2608-2628.
[17]
Poggio P, Sainger R, Branchetti E, et al. Noggin attenuates the osteogenic activation of human valve interstitial cells in aortic valve sclerosis[J]. Cardiovascular Res,2013,98(3):402-410.
2017, Vol. 28 
